Resistance Data in the Arten Trial

Soriano V. , Arastéh K. , Migrone H. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011; 16: 339–348.

Gupta R. , Hill A. , Sawyer A.W. , Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712–722.

Riddler S.A. , Haubrich R. , DiRienzo A.G. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095–2106.

Lapadula G. , Costarelli S. , Quiros-Roldan E. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008; 46: 1127–1129.

Rey D. , Hoen B. , Chavanet P. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 380–388.